THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 125 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,813 | +1265.5% | 325,985 | +1536.4% | 0.24% | +1047.6% |
| Q2 2023 | $206 | -82.0% | 19,921 | -81.1% | 0.02% | -81.4% |
| Q1 2023 | $1,142 | +76.8% | 105,263 | +82.8% | 0.11% | +41.2% |
| Q4 2022 | $646 | -99.9% | 57,577 | -49.8% | 0.08% | -48.7% |
| Q2 2022 | $1,039,000 | +119.7% | 114,646 | +131.8% | 0.16% | +147.6% |
| Q1 2022 | $473,000 | +129.6% | 49,456 | +254.1% | 0.06% | +85.3% |
| Q3 2020 | $206,000 | -1.4% | 13,965 | +30.0% | 0.03% | +21.4% |
| Q3 2019 | $209,000 | – | 10,745 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Link Fund Solutions Ltd | 5,251,349 | $135,459,000 | 69.86% |
| Chescapmanager LLC | 949,006 | $24,570,000 | 3.61% |
| Baupost Group | 9,309,168 | $241,014,000 | 2.66% |
| Rock Springs Capital Management LP | 655,200 | $16,963,000 | 0.54% |
| Rubric Capital Management LP | 173,400 | $4,489,000 | 0.51% |
| Newtyn Management, LLC | 173,300 | $4,487,000 | 0.41% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $988,000 | 0.17% |
| King Wealth Management Group | 22,500 | $583,000 | 0.15% |
| Virtus ETF Advisers LLC | 29,216 | $756,000 | 0.12% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 452,615 | $11,718,000 | 0.12% |